Related Experiment Video
Updated: Jul 24, 2025
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
Primary Human Leukemia Stem Cell (LSC) Isolation and Characterization
Neslihan Meriç1,2, Fatih Kocabaş3
1Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Türkiye. neslihan.meric@ksbu.edu.tr.
Methods in Molecular Biology (Clifton, N.J.)
|July 10, 2023
Summary
Leukemia stem cells (LSCs), resistant to chemotherapy, are crucial for cancer progression. This chapter details methods for isolating and characterizing human LSCs from patient samples for research and drug development.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Leukemia stem cells (LSCs) drive leukemia progression due to chemotherapy resistance.
- LSCs share surface antigens with hematopoietic stem cells (HSCs), complicating isolation.
- Targeting LSCs is vital for developing effective leukemia therapies.
Purpose of the Study:
- To describe primary human LSC purification and characterization methods.
- To provide insights for LSC isolation in leukemia and lymphoma research.
- To support the development of LSC-targeting drug candidates.
Main Methods:
- Utilizing surface markers like CD34, CD123, CD133, and CD33 for LSC identification.
- Employing magnetic selection (MS) for cell separation.
- Applying flow cytometry selection (FCS) for precise LSC isolation.
Main Results:
- Established protocols for isolating and characterizing human LSCs from patient samples.
- Demonstrated the utility of specific surface markers for LSC assessment.
- Provided a foundation for further LSC research and therapeutic development.
Conclusions:
- Accurate LSC isolation is essential for understanding leukemia and developing new treatments.
- The described methods facilitate LSC purification and characterization from clinical samples.
- This work aids in advancing LSC-targeting drug discovery for leukemia and lymphoma.
